Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Telos Capital Management Inc.

Telos Capital Management Inc. lowered its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 52.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,671 shares of the life sciences company’s stock after selling 4,101 shares during the period. Telos Capital Management Inc.’s holdings in Illumina were worth $511,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Acadian Asset Management LLC lifted its stake in shares of Illumina by 312.5% in the 1st quarter. Acadian Asset Management LLC now owns 2,013 shares of the life sciences company’s stock worth $702,000 after acquiring an additional 1,525 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Illumina by 3.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 237,118 shares of the life sciences company’s stock worth $82,853,000 after acquiring an additional 7,114 shares during the period. Dakota Wealth Management lifted its stake in shares of Illumina by 13.8% in the 1st quarter. Dakota Wealth Management now owns 826 shares of the life sciences company’s stock worth $288,000 after acquiring an additional 100 shares during the period. Sequoia Financial Advisors LLC lifted its stake in shares of Illumina by 16.9% in the 1st quarter. Sequoia Financial Advisors LLC now owns 803 shares of the life sciences company’s stock worth $281,000 after acquiring an additional 116 shares during the period. Finally, Baird Financial Group Inc. lifted its stake in shares of Illumina by 10.2% in the 1st quarter. Baird Financial Group Inc. now owns 48,943 shares of the life sciences company’s stock worth $17,108,000 after acquiring an additional 4,548 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Price Performance

Illumina stock opened at $118.29 on Thursday. The firm has a fifty day moving average of $134.31 and a 200-day moving average of $128.15. The firm has a market capitalization of $18.84 billion, a P/E ratio of -16.12 and a beta of 1.19. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $232.23. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the prior year, the firm posted $0.14 EPS. The firm’s revenue was up 3.6% compared to the same quarter last year. As a group, analysts predict that Illumina, Inc. will post 0.91 EPS for the current year.

Insider Transactions at Illumina

In other Illumina news, CEO Jacob Thaysen purchased 7,330 shares of Illumina stock in a transaction dated Thursday, February 22nd. The shares were bought at an average cost of $135.29 per share, for a total transaction of $991,675.70. Following the transaction, the chief executive officer now owns 14,861 shares in the company, valued at approximately $2,010,544.69. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.17% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. TD Cowen cut shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 target price for the company. in a research note on Thursday, January 4th. HSBC downgraded shares of Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. OTR Global reiterated a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. StockNews.com upgraded shares of Illumina from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Finally, Barclays increased their price target on shares of Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a report on Wednesday, April 10th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $167.70.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.